Skip to main content
C
CorpDigest
Search

Vertex Pharmaceuticals Incorporated

Biotechnology and Genetic MedicinesFounded 1989
Reviewed by Swet Parvadiya
Company data updated: October 2026

Founders

Who Founded Vertex Pharmaceuticals?

Joshua Boger · Founded 1989 · HQ today: Boston, Massachusetts

Who founded Vertex Pharmaceuticals?

Vertex Pharmaceuticals was founded by Joshua Boger in 1989. It is now led by Reshma Kewalramani.

Founders
Joshua Boger
Founded
1989
Headquarters
Boston, Massachusetts
Number of founders
1
Current CEO
Reshma Kewalramani (since 2020)
Where was Vertex Pharmaceuticals founded?
Vertex Pharmaceuticals was founded in Cambridge, Massachusetts, United States in 1989.
When was Vertex Pharmaceuticals founded?
Vertex Pharmaceuticals was founded in 1989.
Who started Vertex Pharmaceuticals?
Vertex Pharmaceuticals was founded by Joshua Boger.
How old is Vertex Pharmaceuticals?
Vertex Pharmaceuticals is 37 years old as of 2026.

Founding Story

Joshua Boger left Merck in 1989 to start Vertex in Cambridge, Massachusetts, around structure-based drug design: using X-ray crystallography and computer modeling of a target protein to design molecules that bind it. The company went public on Nasdaq in 1991. Its first approved products were HIV protease inhibitors developed with GlaxoSmithKline. The 2001 acquisition of Aurora Biosciences brought a San Diego screening operation and a cystic fibrosis research program funded in part by the Cystic Fibrosis Foundation, which became the source of Vertex's CF medicines.

Joshua Boger

Background

Chemist with a Ph.D. from Harvard University who spent the 1980s in medicinal chemistry research at Merck before leaving to start Vertex.

Role at Vertex Pharmaceuticals Incorporated

Joshua Boger founded Vertex in Cambridge, Massachusetts, in 1989 on the idea that drugs could be designed from the three-dimensional structure of a target protein rather than found by large-scale random screening. He led the company as CEO until 2009, a period that covered its HIV protease inhibitor work with GlaxoSmithKline, the hepatitis C program that became INCIVEK, and the cystic fibrosis research collaboration that later produced KALYDECO. The early years of the company were chronicled in Barry Werth's 1994 book The Billion-Dollar Molecule.

Joshua Boger was born in 1951 in Concord. Education: Wesleyan University.

Vertex Pharmaceuticals Incorporated: CEO & Leadership History

Full timeline →

Reshma Kewalramani

Chief Executive Officer and President

2020 – Present

A nephrologist who joined Vertex from Amgen in 2017 and served as Chief Medical Officer before becoming CEO in April 2020; her tenure has focused on diversifying Vertex beyond cystic fibrosis.

Charles Wagner

EVP, Chief Operating and Financial Officer

2019 – Present

As CFO, he ensures the company maintains the massive R&D budget required to develop the highly anticipated non-opioid painkiller (VX-548).

Jeffrey Leiden

Chief Executive Officer

2012 – 2020

As CEO from 2012 to 2020, he transformed Vertex from a struggling biotech with a failed Hepatitis C drug into a massive, highly profitable monopoly in CF treatments.

Joshua Boger

Founder and Chief Executive Officer

1989 – 2009

He led the research that produced the hepatitis C drug telaprevir and the first cystic fibrosis medicines. Matthew Emmens succeeded him in 2009.

Keep researching Vertex Pharmaceuticals

Who Founded Vertex Pharmaceuticals? FAQ

Who was the founder of Vertex Pharmaceuticals?

Vertex was founded in 1989 by Dr. Joshua Boger, an acclaimed medicinal chemist and former senior director of basic medicinal chemistry at Merck & Co.

What was Dr. Joshua Boger's educational and scientific background?

Born in Concord, Massachusetts, Boger earned his undergraduate degree in chemistry and philosophy from Wesleyan University and a Ph.D. in chemistry from Harvard University, studying under Nobel laureate E.J. Corey.

Why did Joshua Boger leave a secure executive career at Merck to start Vertex?

Boger believed that big pharma's traditional method of testing thousands of random chemicals against biological targets was clumsy and inefficient; he wanted to design drugs atom-by-atom using 3D structural biology.

Who provided the initial venture capital financing for Vertex in 1989?

Venture capitalist Kevin Kinsella of Avalon Ventures provided the critical seed funding in 1989, sharing Boger's bold vision of creating an independent, research-driven biopharmaceutical titan.

Who were key members of Vertex's founding scientific team?

Boger recruited top crystallographers and chemists from Harvard and MIT, including Manuel Navia (a pioneer in protein crystallography) and computational modeling experts who built Vertex's computer-aided design systems.

What was Vertex's first major research target in the 1990s?

Vertex initially focused on HIV protease inhibitors and immunosuppressive agents targeting FK506-binding protein (FKBP), designing the protease inhibitor Agenerase (amprenavir), approved in 1999 with Glaxo Wellcome.

Where were Vertex's earliest research laboratories located?

Vertex began in modest leased lab space in Kendall Square in Cambridge, Massachusetts, the epicenter of the emerging biotechnology revolution.

What was the central theme of Barry Werth's "The Billion-Dollar Molecule"?

The book captured the brutal scientific, financial, and psychological challenges of biotech startup life—racing against pharmaceutical giant Merck while running low on capital and battling scientific skepticism.

When did Vertex conduct its Initial Public Offering (IPO)?

Vertex went public on the NASDAQ in 1991 under the ticker symbol VRTX, raising capital to fund its drug discovery pipeline and establish long-term financial independence.

What roles did Joshua Boger hold after stepping down as CEO in 2009?

Dr. Boger served as Chairman of the Board until 2011, later becoming Chair of the Board of Trustees at Wesleyan University and an active philanthropist supporting scientific education and underwater photography.

How did the founder's core scientific philosophy shape modern drug discovery?

Boger's conviction that computer modeling and X-ray crystallography could rationally design molecules is now standard industry practice across every major pharmaceutical company on Earth.

What is Joshua Boger's enduring legacy in biotechnology?

He founded one of the few independent biotechs to survive, grow, and conquer fatal diseases, creating a scientific powerhouse that saved tens of thousands of cystic fibrosis patients worldwide.

Related Founder Profiles

Compare founding stories, origins, and entrepreneurial journeys

Competitor

Regeneron

View Founder Profiles
Competitor

Gilead Sciences

View Founder Profiles
Competitor

Pfizer

View Founder Profiles
Competitor

Abbvie

View Founder Profiles
Competitor

Roche

View Founder Profiles
Competitor

Novartis

View Founder Profiles

Explore Vertex Pharmaceuticals

Core profile pages, founders and related research hubs for this company.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.